East Suffolk and North Essex NHS Foundation Trust
Ipswich, IP4 5PD, United Kingdom
NCT Number: NCT04756518
COVID-19 infection is currently confirmed by a complex, multiple-step procedure starting with a mucosal swab, followed by viral RNA extraction and processing and qPCR.
This study aims to explore a novel method using machine learning and artificial intelligence (AI) algorithm to diagnose COVID-19 infection through the morphological analysis of lymphocyte subset in the peripheral blood. This study will also risk stratify patients with COVID 19 infection based on the above finding along with other clinical, haematological and biochemical parameters with a view to predict clinical outcome with high sensitivity and specificity.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ipswich, IP4 5PD, United Kingdom
This is an observational study which will be carried out at East Suffolk and North Essex NHS Foundation Trust (ESNEFT) in collaboration with University of Suffolk (UoS).
Investigators aim to analyse subsets of lymphocytes in the prospective blood smear slides using machine learning and AI algorithm obtained from participants with a positive qPCR test for COVID-19 who have required a hospital admission. The control group will consist of archived blood smear slide data from patients both with i) non-suspected viral infections, and ii) those with a non-COVID-19 viral infection obtained prior to the emergence of COVID-19 infection in the United Kingdom. In total, 785 blood smear slides will be analysed. The aim of this study is to establish the diagnosis of COVID 19 infection based on lymphocyte morphology on patients with COVID-19 infection from other patients with non COVID -19 viral infections. A high definition single cell lymphocyte image from patients with COVID 19 infection and control group will be analysed using open source histopathology imaging software CellProfiler against very fine cytoplasmic and nuclear details of the cells through supervised and unsupervised machine learning algorithm to identify recurring pattern that is unique to COVID 19 infection. The study will also assess other relevant clinical, haematological and biochemical parameters in conjunction with the above morphological features to develop a risk stratification tool to predict the clinical outcome of patients with COVID-19 infection with high specificity and sensitivity using bioinformatics pipeline.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Determine whether lymphocytes alone can diagnose COVID-19 disease with high specificity and sensitivity, using AI-based image analytical modelling.
Time frame: 6 months
The secondary outcome measure of the study will be to create risk stratification modelling, to aid in predicting the severity and mortality of the infection, based on our above-mentioned, novel diagnostic tool and additional clinical, haematological and biochemical parameters; ensuring high specificity, with consequent facilitated management of patients both in a hospital and outpatient setting. The model proposed intends to use and evaluate the clinical parameters including oxygen saturation at the time of venesection, and other vital statistics, including: pulse, blood pressure and respiratory rate, along with other parameters such as LDH, ferritin, C-reactive protein (CRP), D-dimers, renal function, all together helping to predict disease outcome and severity.
East Suffolk and North Essex NHS Foundation Trust
Other
Rapid Diagnosis of COVID-19 Positive Patients With Artificial Intelligence (AI) Algorithm Using Clinical and Image Analytical Parameters to Evaluate the Lymphocyte Subsets in the Peripheral Blood
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04420247
COVID, COVID-19
Curitiba, Paraná, Brazil
View Trial DetailsNCT04568148
COVID, COVID-19
Kansas City, Kansas, United States
View Trial DetailsNCT04444609
ARDS, Human, COVID-19
London, United Kingdom
View Trial DetailsNCT04335084
COVID, COVID-19
Ventura, California, United States
View Trial Details